



February 14, 2025

To whom it may concern:

Company: Precision System Science Co., Ltd.

Representative: Yu SUGIYAMA, President

(Code: 7707 / Tosho Growth)

Contact: Takeharu Ogura, Controller

Phone: +81-(0)47-303-4800 URL: https://www.pss.co.jp/

## Release for announcement: Revision of the Distribution Agreement with DiagCor Life Science Ltd

Precision System Science Co., Ltd. (hereinafter referred to as "PSS") is pleased to announce the revision of its distribution agreement with DiagCor Life Science Ltd. (Hong Kong, <a href="https://diagcorlifescience.com/en">https://diagcorlifescience.com/en</a>, hereinafter referred to as "DiagCor"). This new agreement aims to enhance the distribution and promotion of PSS's geneLEAD system alongside DiagCor's PCR reagents, marking a significant milestone in the collaboration between the two companies.

## 1. Background of the Agreement

PSS has maintained a longstanding collaboration with DiagCor, utilizing its nucleic acid extraction system, the magLEAD series, in conjunction with DiagCor's CE-IVD reagents, including the GenoFlow™, GenoScreen™ and GenoQuest™ series. To further strengthen this partnership, PSS and DiagCor have agreed to enable fully automated molecular testing through the geneLEAD system. This agreement will support the expansion of the geneLEAD system's distribution territory via DiagCor's established network.

## 2. Overview of DiagCor Life Science Ltd.

• Company Name: DiagCor Life Science Limited

• Chief Executive Officer: Dr. Desmond Hau

• **Headquarters**: 10/F, Stelux House, 698 Prince Edward Road East, San Po Kong,

Kowloon, Hong Kong

• Year Established: 2006

• Website: https://diagcorlifescience.com/en

DiagCor, a subsidiary of the Pangenia Group, is headquartered in Hong Kong and employs over 80 bioscience professionals specializing in molecular diagnostic services. The company is ISO 13485-accredited for its quality management system and continues to excel in the field of molecular diagnostics. As a global pioneer in flow-through hybridization systems and the GenoFlow<sup>TM</sup> assay, DiagCor leads advancements in multiplex technology. It is also actively expanding its portfolio of in vitro diagnostic qPCR assays for open systems, focusing on areas

such as infectious diseases, oncology, and human genetics.

3. Effect on Revenue

The effect of this agreement on the PSS's performance has already been factored into the performance forecast for the current consolidated fiscal year, and there will be no changes to the forecasted consolidated revenue for the period.

[Contact information for inquiries regarding this announcement]

Marketing Department

Precision System Science Co, Ltd.

Phone: +81-47-3030-4801 (Business hours: Monday to Friday, 9:00 AM to 5:00 PM)

E-mail: <a href="mailto:service@pss.cp.jp">service@pss.cp.jp</a>

Website: https://www.pss.co.jp